AmCare Lab has raised nearly CNY 200 million in a Series B+ round of funding. This round of financing was led by CICC Kai Tak Innovative Biomedicine Fund, a subsidiary of CICC Capital, followed by 贝森医疗基金, 粤科金融, and JoinTown.
AmCare Lab was established in 2015. It focuses on providing genetic specialist services like testing and counseling. It's also a biomedical firm that provides clinical inspection and in vitro diagnostic services.
"Using genomic technology to improve diagnosis and treatment paths has become unavoidable," said CICC Kai Tak Innovative Biomedicine Fund chairman Ying Liang. AmCare Lab specializes in the diagnosis, screening, and counseling of hereditary diseases, and it is constantly updating its technology to ensure that patients receive high-quality care.
AmCare Lab has long been favored by investors due to its excellent product capabilities and outstanding growth. This round of funding will go toward improving genomic disease diagnosis, pipeline registration, and the creation of a closed-loop business model that involves both upstream and downstream companies.
According to Dr. Wei Zhang, founder, and CEO of AmCare Lab, with our growing understanding of the serious consequences of genetic diseases, particularly the clinical application of genomic testing technology in the field of birth defect prevention and control, it is critical to expand the use of genomic testing products in hospitals at all levels to effectively improve the quality of newborns and reduce the medical burden on society and family.